Background: Low compliance rates with medication after an acute coronary syndrome (ACS) is a serious public health problem with adverse socioeconomic implications for both patients and their families as well as for health systems in general. The aims of the study are to measure the levels of compliance with medication in the treatment of patients who suffered from ACS and to investigate the factors contributing to the noncompliance.
Methods: The sample consisted of 100 patients hospitalized in the coronary care unit (CCU) of a general hospital.
J Bronchology Interv Pulmonol
January 2016
A 34-year-old man presented with scanty hemoptysis, orange-colored expectoration, and mild dyspnea. He was in an enclosed building taking part in a military training exercise inhaling an orange-colored smoke from a smoke grenade ignition. His symptoms developed immediately after the initial exposure but he sought medical assistance 20 hours later because of their persistence.
View Article and Find Full Text PDFJ Bronchology Interv Pulmonol
April 2015
Bronchoscopic drainage of a pyogenic lung abscess is an established therapeutic approach in selected patients in whom conventional antibiotic therapy fails. This intervention has also been undertaken in patients with abscess owing to underlying lung cancer and prior combined radiochemotherapy. However, this procedure has rarely been performed in cavitary lesions of advanced tumor origin before initiating any chemotherapy/radiotherapy scheme.
View Article and Find Full Text PDFObjective: Evaluate the results obtained from Quantitative Fluorescent (QF)-PCR and conventional karyotype analysis to determine the advantages and disadvantages of dual testing in prenatal diagnosis.
Methods: From 1 June 2006 to 1 June 2010, dual testing by QF-PCR and karyotype analysis was performed in 13,500 prenatal samples. The rates of concordant results between the two methods were evaluated and the rates of clinically significant chromosomal abnormalities undetected by QF-PCR were assessed.
J Oncol Pharm Pract
March 2013
Pemetrexed is indicated for locally advanced or metastatic non-squamous non-small-cell lung cancer as an initial treatment in combination with cisplatin or after prior chemotherapy as a single agent. It is generally a well-tolerated drug. The most common adverse reactions (incidence ≥ 20%) with single-agent use are fatigue, nausea, and anorexia.
View Article and Find Full Text PDF